Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary
November 3, 2021
Earnings Call Speaker Segments
Joanna Siegall
executiveGood afternoon, and thank you for being with us on today's call. Robert Blum, who serves as our President and Chief Executive Officer, will kick things off with a look at the quarter and what has happened recently; after that, Fady Malik, our EVP of Research and Development, will give an update on omecamtiv mecarbil, covering additional analyses from GALACTIC-HF that were presented recently, plus where we stand on the next steps with the FDA. Following him, Stuart Kupfer, our SVP and Chief Medical Officer, will update everyone on the aficamten development program: he'll recap results from cohorts one and two of REDWOOD-HCM, go into more detail about ongoing activities in REDWOOD-HCM, and walk through the design of SEQUOIA-HCM, the Phase 3 clinical trial we have planned for aficamten in patients with obstructive HCM. He will also talk about early progress in COURAGE-ALS, our Phase 3 clinical trial of reldesemtiv that is ongoing in patients with ALS. After that, Andrew Callos, our EVP and Chief Commercial Officer, will cover our go-to-market strategy for omecamtiv mecarbil as well as our plans for developing the cardiovascular franchise and commercializing aficamten. Robert Wong, our VP and Chief Accounting Officer, will give a financial overview covering the quarter just ended, and Ching Jaw, our SVP and Chief Financial Officer, will talk about strategic planning, our financial outlook, and corporate development strategies, and then Robert Blum will offer some concluding thoughts along with the key milestones we expect for the rest of 2021. Please be aware that parts of what we discuss below, including how we answer questions, include statements about future events and performance instead of historical facts, and these are forward-looking statements. What actually happens could differ materially from what these forward-looking statements project. Information about factors that might make our actual results differ materially from what these forward-looking statements describe can be found in our SEC filings, among them the current report on our third quarter 2021 financial results, which was filed today on Form 8-K. We have no obligation to update any forward-looking statements after this call ends; with that, I'll hand the call over to Robert.
Robert Blum
executiveThank you, Joanna, and once more I appreciate all of you being here on today's call. Our third quarter proved highly productive, defined by substantial advancement throughout every one of our later stage programs. The standout item was the favorable data we reported from the Phase II clinical trial REDWOOD-HCM, showing both efficacy and safety for Aficamten, our next-in-class drug candidate, in individuals suffering from obstructive hypertrophic cardiomyopathy. As we have stated, the outcome of this study matched the elevated bar we set, and the physician community responded positively. Stuart is going to go into greater depth regarding that data shortly. Also during Q3, we were glad to finish enrolling Cohort 3 of REDWOOD-HCM, which, as you may remember, included patients who were additionally taking disopyramide, a medication frequently given to those with more severe HCM. We anticipate reporting Cohort 3 data during the first quarter of 2022. After earlier discussions with FDA, through which we obtained input regarding the design we planned for our trial, we keep pushing forward with preparations for SEQUOIA-HCM, the Phase 3 clinical trial of Aficamten in patients who have obstructive HCM, as we recently described, and Stuart will say more. The design of this trial aims to potentially show a meaningful gain in exercise capacity while assessing safety across a broad population of symptomatic obstructive HCM patients. We are engaging with sites globally, among them numerous that took part in REDWOOD-HCM and are eager to join SEQUOIA-HCM as well, and we anticipate launching this study before long. Turning to the heart failure program, we kept up work supporting our intention to file an NDA for omecamtiv mecarbil, and we are still on schedule for our target of submitting during this year's fourth quarter; Fady will speak further about that shortly. In addition, as we laid out at our recent Analyst and Investor Day, we are achieving considerable headway in sharpening and carrying out our go-to-market strategies for omecamtiv mecarbil across multiple work streams, which Andrew will describe shortly. These commercial readiness efforts reflect an enormous amount of work from our expanding commercial organization, backing our go-to-market strategies together with our aim of establishing a cardiovascular business franchise by drawing on shared elements and synergies throughout our business, encompassing our plans both for the possible launch of omecamtiv mecarbil and a possible upcoming launch of Aficamten. As Fady will cover, in the third quarter we shared further findings from GALACTIC-HF, led by an analysis of black patients who had been enrolled in GALACTIC-HF, demonstrating that the treatment effect of omecamtiv mecarbil among black patients aligned with the treatment effect seen in the overall population and was likewise comparable to the effect noted among white patients in the trial; this discovery matters. That is because black patients generally face a greater risk of heart failure and frequently experience worse outcomes. Also, a look at the severe heart failure subgroup within GALACTIC-HF came out in the Journal of the American Medical Association Cardiology, and it shed light on a bigger treatment effect relative to the overall group of patients who were studied. Alongside this key manuscript ran an editorial proposing that we acknowledge a new classification covering a subset of severe heart failure patients whose persistently high unmet need reflects a growing heart failure population that adds ever more to the clinical burden and the economic burden of this illness. Last, we were happy during the latest quarter to start enrolling patients in ALS, our Phase 3 study of reldesemtiv among people who have ALS. Investigators and physicians treating ALS patients judged the findings of the Phase 2 trial FORTITUDE-ALS to be compelling, and moving ahead to Phase 3 is a thrilling and significant step for this program, consistent with how devoted we are to the ALS communities. Those communities are pursuing new medicines with greater insistence, and the FDA together with public policymakers appear to be answering these louder demands for action more and more; this is a hugely important moment for our company. We're growing our teams and our capabilities, since we now stand at the threshold of a major shift from a company focused on R&D into one that is commercial as well; delivering ourselves on the promise of our science has always been our strategic vision, and we are nearer to that today than at any prior point. These are certainly exciting times, yet how we carry out those plans is what will count. Robert will cover our present financials, and Ching will discuss our progress and prospects, continuing our long-standing practice of diversifying how we access capital via partnering as well as structured financings, guided by annual strategic planning; with that, I'll now hand the call to Fady to go into greater detail about developments tied to omecamtiv mecarbil.
Fady Malik
executiveRobert, I appreciate that. You mentioned the results from additional GALACTIC-HF analyses, which we presented this quarter at the Heart Failure Society of America Annual Scientific Meeting. Those findings verify that outcomes for omecamtiv mecarbil in black patients within GALACTIC-HF aligned with what we observed in the larger population, and consistent with the study's overall results, these were primarily driven by a reduction in heart failure hospitalizations and heart failure events. The treatment effect observed in black patients was also comparable to the one identified in white patients. When it comes to heart failure studies conducted recently, the trial that randomized the greatest number of black participants was GALACTIC-HF. Looking at the U.S. portion of that enrollment, 29% were black. This is significant for two reasons: black patients have long been underrepresented in clinical research, and they face a greater likelihood of developing heart failure along with poorer results. The reasons behind these worse outcomes are multifaceted. Still, it is a positive sign that the possible advantages of omecamtiv mecarbil treatment remain uniform within this population. Shifting to the subject of heart failure patients at elevated risk, a manuscript came out in JAMA Cardiology three weeks ago called assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure. Immediately following the first look at the data in late June, presented at Heart Failure 2021 and the International Congress of the European Society of Cardiology, came an analysis led by Dr Michael Felker and his co-authors. They looked at how omecamtiv mecarbil performed in terms of treatment effect. Their focus was the primary composite endpoint among GALACTIC-HF participants who met modified criteria for severe heart failure, drawn from the advanced heart failure physician statement issued by the heart failure association of the European Society of Cardiology. Those falling into this subgroup showed NYHA Class III or IV symptoms, ejection fractions at or below 30%, and a heart failure hospitalization during the six months before enrollment. In GALACTIC-HF, about 30% of enrolled patients satisfied these criteria, and their win rate was roughly double that of patients who did not have severe heart failure. In this post-hoc analysis, patients with severe heart failure who were given omecamtiv mecarbil showed a significant treatment benefit on the primary endpoint, with a hazard ratio of 0.8 to 0, while those without severe heart failure showed no significant treatment benefit, with a hazard ratio of 0.99. For cardiovascular death, or in qualitatively similar patients whose heart failure was severe, there was a trend toward treatment benefit from omecamtiv mecarbil, whereas patients without severe heart failure did not show this. For patients suffering from severe heart failure and those without it, omecamtiv mecarbil showed the same level of tolerability, and there were no meaningful shifts in blood pressure, kidney function, or potassium levels when compared with placebo. Accompanying that paper was an editorial authored by Dr. Yancey Adrian Hernandez and Greg < >, entitled identifying treatments for Stage C2 heart failure. In this piece, Stage C2 is put forward as a proposed new addition to the four stages of heart failure that are currently defined — A through D — and it would serve to capture those severe heart failure patients who might deserve priority for further impactful therapy. During our latest Analyst and Investor Day, this considerable unmet need was one of the central subjects in the panel discussion. Even when guideline-directed medical therapy, or GDMT, is available and followed, individuals whose heart failure is worsening continue to experience a high rate of events. Doctors Alanna Morris and Tarek Ahmad, both heart failure specialists at major academic medical centers, explained to us that getting patients onto GDMT can be difficult, since a lot of them cannot tolerate the medications because of side effects. Then there's omecamtiv mecarbil, a possible add-on treatment featuring a novel mechanism of action that might serve as a complement to and alongside current therapies without raising cardiac mortality. According to physician feedback, their outlook is favorable regarding the clinical utility of omecamtiv mecarbil as one more therapeutic choice with a solid safety and tolerability profile, and they see a clear need for a therapy such as omecamtiv mecarbil to fit into routine practice. Turning to the next point, enrollment for METEORIC-HF wrapped up at the close of the second quarter, and throughout the third quarter we kept carrying out the trial. This study will shed light on how omecamtiv mecarbil might help with another crucial element of bettering the lives of those with heart failure, namely enhancing their exercise capacity. One thing we hear often from people living with heart failure is that they struggle with or can't manage routine daily activities, but the options available right now barely move the needle on how well patients can exercise or how long they can keep going. We expect to wrap up METEORIC-HF before the year is out, and we're eager to present the findings during the first part of 2022. On top of that, in Q3 we met with the FDA to help us get ready for and file our new drug application, or NDA, for omecamtiv mecarbil; a pre-NDA meeting has now concluded, and it affirmed that it makes sense to submit the chemistry manufacturing and control, clinical pharmacology, and non-clinical program sections, as well as how the data sets are formatted, the integrated summary of safety, and the rest of the NDA pieces. In addition, we held discussions with the FDA regarding the test for omecamtiv mecarbil plasma levels — in particular whether it might be required to help determine dosing, and what the regulatory route would be for implementing that. Taken together, these interactions provided guidance on specific portions of our NDA, and submission remains scheduled for this quarter. That keeps us moving toward our objective of filing our NDA with the FDA. Meanwhile, we continued broadening both the scope and the reach of our medical affairs efforts, adding therapeutic area lead medical directors and placing additional field-based medical sciences personnel; we have established a compliant structure for an investigator-sponsored studies program, which comes at an opportune moment since requests for potential collaborative activities have started coming in. The team is busy finalizing their scientific platform. When it comes to omecamtiv mecarbil, the compound that underpins our interactions with healthcare providers, we've additionally begun choosing a vendor to build a medical contact center, so we're ready to handle inquiries for medical information or route specific questions to the right people for an answer. With that said, I'll hand things over to Stuart, who will share an update on aficamten and reldesemtiv.
Stuart Kupfer
executiveAppreciate it, Fady. In Q3, back in September, we shared the complete data from Cohorts 1 and 2 of REDWOOD-HCM, our Phase 2 study of aficamten, at the Heart Failure Society of America Annual Scientific Meeting held in Denver. As we've noted before, those findings came out positive and back moving aficamten into Phase 3, which I'll get to shortly. As we'd already reported from REDWOOD-HCM, taking aficamten for 10 weeks produced statistically significant drops from baseline versus placebo in the mean resting left ventricular outflow tract, or LVOT, pressure gradient, along with the mean post-valsalva LVOT gradient. Most patients on aficamten — 79% in Cohort 1 and 93% in Cohort 2 — hit the treatment target, which was defined as a resting gradient under 30 millimeters of mercury and a post-valsalva gradient under 50 millimeters of mercury at week 10, versus 8% on placebo. These LVOT gradient decreases were dose-dependent, meaning patients saw larger LVOT gradient reductions as aficamten doses went up. LVOT gradient reductions showed up within two weeks of starting treatment, peaked between two and six weeks after dose titration began, and held steady through the end of treatment at 10 weeks. Reversibility of both LVOT gradient and ejection fraction declines was seen once aficamten was stopped, with values coming back to baseline by the close of the two-week washout period. Patients also saw statistically significant drops in NT pro BNP, and aficamten treatment was tied to better New York Heart Association functional class, with a substantial number of patients improving by at least 1 class. As we said before, aficamten was well tolerated. Adverse event rates looked similar across treatment arms. And no treatment-related serious adverse events occurred. Importantly, there were no treatment interruptions or discontinuations. Director of the Hypertrophic Cardiomyopathy Center at Tufts University School of Medicine, who presented the REDWOOD-HCM results at HFSA, highlighted the potential clinical utility of aficamten given that resting LVOT gradients were eliminated in nearly all patients. Dr. Maron also spoke about the substantial improvement in heart failure symptoms, the rapid onset and reversibility of effect, the ability to titrate precisely using echo guidance, and the absence of dosing interruptions for low ejection fraction. At the conference, we also got a positive response from physicians managing HCM patients, who voiced enthusiasm about the results and about a medication that potentially could serve patients with symptomatic obstructive HCM who aren't responding to current standard of care therapies. All in all, we're very encouraged by the results so far and how they might translate into clinical practice. During the quarter, we also finished enrollment in Cohort 3 of REDWOOD-HCM, where patients with obstructive HCM who are on disopyramide as background therapy receive aficamten in an open label manner. This group will also help us determine whether to include this modest yet significant patient group in the Phase 3 study we're planning. Also, throughout Q3, we kept adding patients to REDWOOD-HCM OLE, which is the open-label extension portion of REDWOOD-HCM. Now that we have favorable data from REDWOOD-HCM, we've been busy with outreach and launch preparations for SEQUOIA-HCM, the Phase 3 clinical study we intend to run for aficamten in people who have obstructive HCM. During our Analyst and Investor Day gathering in October, we laid out the trial's design, and I'll go over it briefly here. SEQUOIA-HCM is an international, randomized, double-blind, placebo-controlled clinical study crafted to assess aficamten in individuals with symptomatic obstructive HCM who are on background medical therapy, over a span of 24 weeks. The main goal is to assess the shift from baseline to week 24 in peak oxygen uptake, or peak VO2, as measured through cardiopulmonary exercise testing, or CPET — a gauge of exercise capacity — among the secondary objectives. We're looking into the change in Kansas City Cardiomyopathy Questionnaire clinical symptom score regarding New York Heart Association functional class at Week 12, to assess a possible early gain in heart failure symptoms, and once more at week 24. Our plan is to randomize 270 patients in a 1:1 ratio to either aficamten or placebo, on top of standard of care. Every patient will get as many as four escalating doses of aficamten or placebo, with dose optimization tied to hitting echocardiographic targets. The beginning dose will be 5 milligrams taken once per day, escalating to 10, 15, or 20 milligrams once daily as required to reach target gradients. Those four doses were chosen from the REDWOOD-HCM findings to help pick the ideal dose for every patient and to maximize each person's benefit-risk profile. Study launch efforts, regulatory submissions, and IRB filings are in progress. With the initial site initiations already done, drug product availability and early 2022 will allow screening and enrollment of the first patients in this trial to begin. Anticipating enrollment of patients with obstructive HCM from China in SEQUOIA-HCM, we keep working closely with our partner Ji Xing Pharmaceuticals. Ji Xing just wrapped up a Phase 1 study assessing single and multiple doses of aficamten in healthy Chinese subjects. The pharmacokinetic findings resembled those seen in the Caucasian populations enrolled in our Phase 1 study of aficamten run in the U.S., and likewise demonstrated dose-proportional pharmacokinetics alongside a safety and tolerability profile akin to placebo. This study's findings back the submission of the clinical trial application and the enrollment of patients with obstructive HCM in China. On the neuromuscular side, as Robert noted, throughout Q3 we started enrolling patients in COURAGE-ALS, the Phase 3 clinical trial of reldesemtiv in ALS. COURAGE-ALS will enroll roughly 555 patients with ALS, randomized 2 to 1 to get reldesemtiv or placebo for 24 weeks, then a 24-week stretch in which every patient will receive reldesemtiv. The main measure we're looking at is how much ALSFRS-R shifts between the starting point and week 24. That's a functional rating scale showing how ALS moves forward. When we were putting COURAGE-ALS together, we brought in input from patients and caregivers so we could take away major obstacles standing in the way of joining a clinical trial, and to make things easier on patients. We're also trying to keep reldesemtiv available on an ongoing basis for every patient who finishes COURAGE-ALS, plus those who took part in our earlier ALS study — that reflects our aim of making sure access is ethical and fair for patients who need it. With that, I'll hand things over to Andrew, who will talk about how we're doing on the go-to-market strategy for omecamtiv mecarbil.
Andrew Callos
executiveThank you, Stuart. Across Q3, we moved our commercialization plan forward for omecamtiv mecarbil, and it was a pleasure to share details at the Analyst Investor Day we held recently. A handful of points about that plan are worth walking through on this call. To begin, the approach we take to market rests on a gated build, with the overall planned spend to be adjusted gradually as events that reduce risk take place, for example NDA submission, NDA filing, and FDA approval. As an illustration, roughly 10% to 15% of the commercial FTEs we intend to have are on board at present, yet fewer than 1/3 of the entire headcount will be hired once the NDA has been submitted — a level of commercial recruiting that is enough to get ready for launch. As Robert noted, we brought on an experienced group to carry out this commercialization plan, and at this point our complete leadership team is in place, along with our account manager team, whose job is calling on payers, and almost the whole of our marketing function. Four central pillars underpin the plan: insights, education, access, and support. Insights refers to holding a really deep grasp of who the worsening heart failure patient is, the places where that patient receives treatment, and which cardiologists are the ones managing their care. Education means that should omecamtiv mecarbil win approval, we must then make certain cardiologists plainly grasp the data behind our label, among it the evidence for the potential benefit of omecamtiv mecarbil in the subset of patients living with worsening heart failure. Access covers our intention to offer an affordable co-pay to the majority of patients as quickly as we can following launch. Lastly, support describes the programs we will make available for patients, such as co-pay assistance for commercial patients, a patient assistance program, and educational services. To help reach our aim of commercial — of affordable access, our payer account management team sat down with every major payer during Q3; we made introductions for our team and our company while getting payers engaged in a shared grasp of the unmet need in heart failure. As further backing for access, our health economics and outcomes research colleagues keep generating outcomes research, aiming at multiple publications. During 2022, those publications are meant to document the value of omecamtiv mecarbil, as shown through meaningful decreases in resource utilization, intensity, and cost. While getting ready for the possible launch of omecamtiv mecarbil, we are at the same time developing our cardiovascular franchise strategy in line with our plan for the possible launch of aficamten, keeping our corporate objective in mind of delivering multiple medicines to market over the coming years. Several synergies are the foundation of this strategy. First, among the cardiologists treating these patients, there is an 80% overlap between the cardiologists who manage heart failure patients and those who manage HCM. Cost efficiency is a further synergy, since we will share fuel cells, fueled medical, shared services, and systems throughout the whole organization. Once relationships have been established and systems built to back the launch of omecamtiv mecarbil, we are well positioned to speed up and streamline the possible launch of aficamten. Working here at Cytokinetics right now is a genuinely thrilling moment, since we keep expanding our staff and moving our initiatives forward. We still need to keep in mind what fuels this drive: the people we serve, plus the obvious gap in care that exists for both heart failure and HCM. So with that said, I'll hand things over to Robert Wong, who is going to give everyone an update on our financials.
Robert Wong
executiveAppreciate it, Andrew. I'll walk through where we stand on cash revenue and spending, and after that Ching will go over the financial outlook along with corporate development strategies. If you want additional specifics on what we actually delivered in the third quarter of 2021, those are in the press release that went out earlier this afternoon; we closed the third quarter holding roughly $668.9 million across cash and investments. Most of what we brought in during the third quarter of 2021 was driven by recognition of a $5 million milestone from Ji Xing Pharmaceuticals tied to the expected launch of SEQUOIA-HCM. R&D expenses for the third quarter of 2021 rose to $48.4 million, compared with $24.2 million in the third quarter of 2020, largely because we spent more on clinical development work across our cardiac muscle inhibitor programs. On top of that, we took on transition costs stemming from winding down our Amgen collaboration and from buying roughly 7.3 million of materials from Amgen, which covered manufactured quantities of the active pharmaceutical ingredients for omecamtiv mecarbil, and with that our purchase commitment is complete. Over 70% of R&D expenses went toward our cardiovascular programs, which is what we expected given the work around transitions from our Amgen collaborations, acquiring manufactured quantities of active pharmaceutical ingredients, ongoing efforts tied to METEORIC-HF, and our cardiac myosin inhibitor programs as well, which take in ongoing activity for REDWOOD-HCM plus start-up work for SEQUOIA-HCM. The rest of our expenses came from our early research and skeletal muscle program activity. G&A expenses for the third quarter of 2021 totaled $26.2 million, an increase from $12.3 million in the third quarter of 2020, mostly because of higher outside spending ahead of a possible commercial launch of omecamtiv mecarbil in 2022. That includes personnel-related costs such as stock-based compensation and facilities costs for our new building; and at this point Ching will go over our financial outlook and corporate development strategies.
Ching Jaw
executiveThank you, Robert. Consistent with what we do each year, we just finished a thorough strategic planning effort, followed by a presentation and discussion with our Board. This time around, the plan centered on putting priority on our growing clinical pipeline, so that we concentrate on R&D programs drawing on our core strengths and competitive edges in muscle biology, while also targeting opportunities with significant unmet need that could offer strong return on investment potential. Beyond that, we stress-tested ways to bolster our research pipeline through outside collaborations capable of supplementing and reinforcing innovation happening internally. Finally, during this year's strategic planning effort, we zeroed in on rigorously assessing and reshaping the strategy for our cardiovascular and neuromuscular business franchise, aiming to keep capturing lifecycle management value from our furthest-along drug candidates: omecamtiv mecarbil, Aficamten and reldesemtiv. To review our cash position, we closed the third quarter holding roughly $669 million in cash, a figure that includes $297 million brought in during Q3 via an equity offering, net of expenses. So our pro forma cash at year-end 2021 should land somewhere between $600 million and $610 million, which gives us over three years of cash runway based on our updated net cash utilization guidance of $195 million to $215 million for 2021. That reflects the possible commercial launch of omecamtiv mecarbil along with funding for 2 Phase 3 clinical trials, SEQUOIA-HCM and COURAGE-ALS. We do anticipate that our cash burn rate across 2022 and 2023 will rise compared with 2021 spending, and we'll give guidance on that matter during our fourth quarter earnings call, set to take place in early 2022. As we've said before, we keep looking for ways to shore up our balance sheet, and in the third quarter we moved forward with partnering and structured financing talks that fit our corporate development strategy. Throughout the quarter, we kept talking with prospective co-development and co-commercialization partners regarding omecamtiv mecarbil, and also aficamten, with particular emphasis on business development across Asia and other complementary geographies where we have no plans to go to market on our own. Our intention is to hold onto North American and possibly European rights for development and commercialization of both omecamtiv mecarbil and aficamten; at the same time, we've been pushing ahead with conversations involving multiple entities and funds holding share interest tied to structured financings, including royalty monetization and a structured deal. All of this is meant to further back the commercial launch of omecamtiv mecarbil and our continued, expanded development objectives for aficamten. We aim to get these deals closed in the fourth quarter, which might let us finish the year with two to three years of forward cash runway, even though we expect spending during 2022 and 2023 to exceed what we expect to spend this year. As you're aware, our company has consistently rested on a solid financial base, and we've got a well-established record of completing deals that don't dilute equity in order to back our ongoing expansion and advancement; this deal should wrap up during the current quarter; we feel that, both financially and strategically, we're set up to ask that you and the possible introduction of omecamtiv mecarbil and keep pushing forward our pipeline along with our business franchise plans. So with that, I'll hand the call back to Robert Blum.
Robert Blum
executiveThanks, Ching. In the vision we outlined back in 2020, with 2025 in mind, we established a number of objectives — among them, securing regulatory clearances for a minimum of 2 drugs coming out of our pipeline, and broadening our discovery platforms. During the quarter just passed, alongside the strides we made clinically, regulatorily, and commercially, we undertook efforts aimed at widening our research footprint for the years ahead. Looking past even 2025, we keep moving forward as leaders in muscle biology, concentrating on populations with high unmet need. Over the coming year, you will hear additional details about what we are doing, since we have stretched our muscle biology emphasis beyond the bio-mechanics of muscle contractility into the energetics, growth, and metabolism of muscle, with drug candidates based on novel mechanisms progressing through development. Although a great deal of our attention has gone to our programs in cardiovascular disease, as you heard when we began COURAGE-ALS, our dedication to the ALS communities has not wavered. In that spirit, we recently gave data from our finished ALS clinical trials to the PRO-ACT database — that name stands for pooled resource open access ALS clinical trials. Members of the research community can access PRO-ACT, and it holds more than 10,000 de-identified clinical patient records drawn from numerous completed clinical trials, which offers a potent instrument for pushing ALS research forward, as well as combined observations regarding disease progression and epidemiologic data. We are going to donate data from 3 completed ALS trials — BENEFIT-ALS, VITALITY-ALS, and FORTITUDE-ALS — representing information from nearly 600 patients; we are glad to be collaborating with the ALS Association, with Price for Life, and with the Neurological Clinical Research Institute at Mass General in order to share this data with the ALS communities to which all of us are so crucially committed. To further show our commitment to patient communities in the quarter, we renewed our partnership with Cure SMA to boost education, awareness, public policy, and fundraising for spinal muscular atrophy, and we also unveiled the 4th Annual Cytokinetics Communications Fellowship Grant program, which will give out a total of $100,000 in grants to patient advocacy organizations in heart failure, in HCM, in ALS, and in SMA, in order to support greater capacity in communications and outreach. As 2021 draws to a close, we reflect on our highly satisfying progress and achievements, and we look toward what could be a watershed year for our company. We anticipate finishing 2021 with 2 separate programs moving ahead in Phase 3 clinical trials, with our first possible medication heading toward a possible approval and commercial launch — all of it built on the foundation of ongoing innovations in muscle biology aimed at patients who depend on us and in areas where our leadership provides hope for diseases tied to muscle dysfunction and weakness. We look forward to sharing further updates about our ongoing progress, and we welcome your questions and feedback. Now let me summarize our expected milestones for the rest of 2021. Regarding omecamtiv mecarbil, our plan is to file an NDA with the FDA during this year's fourth quarter. We likewise anticipate wrapping up the running of METEORIC-HF by the time the year ends, with data readouts anticipated in early 2022. Turning to aficamten, we look to carry on study start up, including regulatory filings, IRB submissions, and site readiness work taken together for SEQUOIA-HCM, along with drug product being available in early 2022. We foresee the beginning of screening plus enrollment of the initial patients in that trial; and as for reldesemtiv, our expectation is to finish enrollment of COURAGE-ALS across what remains of this year. And when it comes to our ongoing research, we expect to push forward new muscle directed compounds, carry out IND enabling studies, and possibly move one to two potential drug candidates into clinical development during the next year. Operator, given that update, we can now open the call up to questions please. Hello, Dane.
Dane Leone
analystThanks. Hello, Robert, and to everyone on the team. I appreciate you fielding our questions, and congratulations on all of the recent announcements. I have just a couple, if that's alright. To start, could you share additional detail regarding how large and comprehensive the SEQUOIA-HCM study is, particularly as we consider, first, how to model the costs involved, and second, how long the trial will take to conduct? Would it be reasonable to treat the EXPLORER-HCM study as a comparable benchmark in terms of its size, its scope, and the number of patients it needed to enroll? My next question is about going a bit deeper into the omecamtiv submission. I realize this has come up already, but regarding your ongoing back-and-forth updates with the FDA, I'd welcome any further detail on how broad or large the label might be with respect to baseline left ventricular ejection fraction. Thanks.
Robert Blum
executiveAbsolutely. Those are good questions. I'll begin, then hand things over to Fady. He might also bring in Stuart for more detail. Regarding SEQUOIA, I don't believe we'll be offering any particular financial guidance. Until we begin giving patients doses, it could be too soon for that. Still, we can definitely share a few points for you to use when building your projections — for example, our anticipated timeline for enrollment and how long the study will run. I'm hoping that proves useful, and you're already aware of how many patients we intend to enroll. So let me hand things over to Fady, who can start by discussing our expectations for enrollment — the site count, the nations involved, that sort of thing. At that point, probably after we begin giving doses — which I'd guess happens at the start of 2022 — we'll be able to give a clearer picture of what we expect the impact on our costs to look like, and after that I'll address the other thing you asked.
Dane Leone
analystOkay, thank you, Robert. My understanding is that our enrollment target for SEQUOIA is roughly 270 patients, a somewhat higher figure than what was used in roles and explore. The overall size and reach seem similar, as do matters such as the count of sites; we'll likely bring in a handful more locations than explorer had across close to 12 countries and considerably beyond 80 sites. In the end, once this study is completely activated, our intention is to work aggressively and get patients signed up as fast as we can. Still, particular constraints exist when it comes to getting a study started and similar matters that can't easily be accelerated; once our sites are running, my belief is that enrollment would move quite quickly.
Robert Blum
executiveNow, your next question had to do with the NDA and the way we're thinking about what might fall inside the NDA indication statement and beyond that; specifically, regarding ejection fraction. As we've said before, our view is that patients whose EF sits below 30% appear to gain substantially more than others in GALACTIC, and we genuinely believe that for omecamtiv mecarbil in heart failure patients, that's the place the label ought to aim; therefore we hold hope that data, graphics included, might make it into the label eventually if approval comes, though clearly that decision rests with FDA review, yet from the discussions we've been having, as Fady can explain further, we feel encouraged that they'd be supportive and aligned with other actions the FDA has taken. Fady, is there anything you'd like to add?
Fady Malik
executiveWell, no — what I mean is, we've clearly already talked this over with the FDA, and whatever ultimately goes into the label is going to come out of the negotiations when we sit down to negotiate that label. Broadly speaking, though, I'd say they're behind the idea that the label ought to show where a drug's benefit is concentrated, which gives physicians what they need to use the drug in the best way possible. And when you look at it that way, EF is clearly a key indicator.
Robert Blum
executiveAnd it's not just the label either. My hunch is that this could eventually shape the way omecamtiv mecarbil gets written into guidelines as well, and you picked up a hint of that from a few of the publications Fady mentioned when he was speaking.
Dane Leone
analystThat's great. I really appreciate it, and well done.
Robert Blum
executiveThank you, Dane.
Robert Blum
executiveHey, Joe.
Joe Pantginis
analystHello, everyone, good afternoon. I appreciate you taking my questions. For my first question, I'd like to concentrate on the idea that this is a really critical period for execution and logistics at your company. Having said that, I'll build off what Stuart mentioned, and Robert, you also brought it up regarding drug availability for early next year and carrying out COURAGE too. Given any expected problems with the global supply chain situation we're currently witnessing, do you believe you've needed to make any extra preparations for these trials, whatever that might involve, including drug availability?
Robert Blum
executiveExcellent question, and I believe this may be the first instance during one of these earnings calls where we've actually received a question concerning the supply chain. It's something we're intensely focused on at present, since we're not just starting these sizable Phase III trials, but we're also preparing to supply omecamtiv to the market, and clearly, had we remained in partnership with Amgen, that would have been an area where we'd have depended on them, but today that responsibility falls on us. We're doing well with contracts, along with converting drug substance into drug product and similar tasks, and SEQUOIA's study startup work is moving along well. We advanced quite quickly from finishing Cohorts 1 and 2, reporting their results, holding meetings with FDA, and getting ready to launch SEQUOIA — all of which happened within a fairly brief period, so it appears things are progressing well. That applies both to backing clinical trials and to commercialization. However, we're establishing the supply chains. Simultaneously, we're carrying out the delivery of drug product into clinical trials, so this is something I believe will remain a priority for senior management, since it enables our success. Up to this point, the positive news is that we're collaborating with some of the same contract manufacturing organizations that we've had long-standing relationships with, and there could be chances to consolidate programs among them, so we'd be working with them across more than one program. We concentrate on small molecule drug candidates, and in that sense, it's not as though we're handling an extremely novel approach to supply, yet we still must guarantee capacity and deliverable timelines, and that's where our focus lies. Fady, is there anything you'd like to add?
Fady Malik
executiveNot really — your summary covers it. Still, we've managed to keep moving forward with getting drug supplies out for our trials and similar efforts. The main bottleneck, I'd say, comes down to how much unused room exists within the supply chain. Quite simply, a great deal of slack has already been pressed out of it. That means you need to think carefully about the way you schedule things.
Stuart Kupfer
executiveAdditionally, allow me to mention that Andrew and his group are highly dedicated to the transition from the producers, as well as the subsequent logistics tied to distribution and every effort involved in making certain that patients receive dependable supplies of the drug. That also relates to possible patient hub services and similar offerings. As time goes on, I anticipate Andrew will share further details on this with all of you as well.
Joe Pantginis
analystThat's extremely useful, thanks. Then I suppose I have a couple of quicker items. The first is maybe for Ching regarding the finance angle. There's this $7.3 million we owe Amgen for omecamtiv drug product. I'm just wondering how much could remain, whether it carries into later periods, or whether that charge is basically finished? Then, if I caught what Fady said correctly when he talked about omecamtiv's future, I could have sworn he mentioned possible ISTs, which sounded intriguing. So I'd like to know what sorts of studies you may be considering. Thank you.
Fady Malik
executiveYes, I mean…
Ching Jaw
executiveThanks.
Fady Malik
executiveOh. Got ahead, Ching. You go first.
Ching Jaw
executiveSure, Fady, I'll take that first. About the e-payment to Amgen — the $7.3 million in this quarter is the final one of those. As mentioned in our press release covering the nine months that ended September 30, 2021, we've paid them $46 million. That was the full amount, and the $7.3 million was the last installment.
Joe Pantginis
analystThank you.
Fady Malik
executiveRegarding studies started by investigators and sponsors, proposals have started coming in. Naturally, we'll allow them to proceed and determine which ones we're able to back, along those lines. They cover quite a wide spectrum of interest. Some of these individuals are really outside — a portion of them beyond the heart failure group that GALACTIC examined — while others sit inside it. As we start guiding those through, though, I believe we'll share additional detail on them.
Joe Pantginis
analystSure. Understood. Thank you very much.
Fady Malik
executiveThank you.
Robert Blum
executiveHi, Yasmeen.
Yasmeen Rahimi
analystHey, Robert. I really appreciate you fielding my questions; there are a couple I'd like to ask. Perhaps the best starting point is that many of our investors were recently caught off guard by the FDA, given certain moves that were made and which stirred up a rather jittery mood. So the question I'd put to you is this: particularly during these past few months, while you've been in touch with the FDA, what has their tone been like, their body language, how have they come across toward you? If you could expand on that, and on how the discussions unfolded, I believe that would matter a great deal. And then I have one more question to ask?
Robert Blum
executiveOf course. What I'd say is that frequently in circumstances like these, biotech firms mention holding a pre-NDA meeting, they turn in an NDA, it either gets filed or it doesn't, and after that they wait for approval. As for us, across the prior year, we've had a great number of interactions with FDA, both face-to-face before COVID put a stop to that, and afterward too via Zoom interactions and otherwise through documents exchanged in writing. My experience was that FDA proved highly accessible and highly interactive with us, offering guidance that shapes both how our planned NDA submission is formatted and what it contains. So the degree of engagement leaves me quite encouraged, and it should, I hope, bolster our submission, which would hopefully line up with the interest in securing approval. Every one of our questions has been answered to our satisfaction, so that we can now move through the final mechanics of an NDA submission and get that finished during this quarter.
Yasmeen Rahimi
analystThanks, Robert, for that response. Perhaps a supplementary inquiry would be to get a sense from you, when you talk with cardiologists — regardless of whether they work in private practice or in a hospital environment — about how much they value omecamtiv as a novel mechanism of action. Once they learn it is the first myotrope capable of actually enhancing cardiac contraction, does the significance land immediately? I believe that could matter greatly — how crucial is the newness of its mode of action in fueling uptake and their excitement, on top of the remarkable data from black in nature.
Robert Blum
executiveNaturally, discussing uptake at this point is premature, given that the drug is not yet approved, yet definitely, from ad boards and conversations with key opinion leaders conducted by medical affairs, plus market research run by our commercial team, we are receiving quite favorable signals regarding how the innovative mechanism might lead to possible future uptake. Maybe I will hand things to Fady initially to discuss certain of those efforts he is supervising, and after that I will go to Andrew too.
Fady Malik
executiveAbsolutely, Yasmeen. The cardiology community, I believe, clearly grasps the potential position this could occupy, and discovering an agent capable of safely enhancing heart performance while delivering patient benefit has been a goal pursued for a very long time within this area. If you take in the presentation from our Investor Day, you'll probably pick up on a degree of excitement across the 2 conversations we held, yet the sentiment was comparable throughout numerous advisory boards we ran in both the U.S. and Europe. Beyond that, as we reach out to additional stakeholders along the way, we're picking up on their eagerness regarding something novel, while at the same time, we recognize the mechanism behind it and it's sensible — there's a clear rationale for why someone would choose to use it.
Andrew Callos
executiveAndrew here. What I'd add is this: in our conversations with physicians, the mechanism by itself generates real excitement, yet it also gives them a basis for confidence when weighed against the data, against whatever evidence we've generated. So once they consider the mechanism alongside that evidence and see how strongly it lines up with unmet need, they're facing a situation where options are dwindling for patients unable to tolerate guideline directed medical therapy. Options also run short when what's required is something that could serve as an add-on, one that's neutral on kidney, neutral on blood pressure, for patients who are working. And when the discussion turns to an add-on with those kinds of effects, they get quite enthusiastic, and that becomes a solid reason for confidence, with the mechanism kind of sealing it. So for a very specific subset of patients, we're seeing considerable enthusiasm regarding the product.
Yasmeen Rahimi
analystThank you for the answer.
Robert Blum
executiveThank you.
Robert Blum
executiveHey, Jeff.
Jeff Hung
analystHey, Robert. Appreciate you taking the questions. Earlier you said that discussions with payers regarding omecamtiv mecarbil had mostly been introductory — I'm just wondering whether there's anything new you can share about what payers are saying.
Robert Blum
executiveAbsolutely, I'll hand things to Andrew for that.
Andrew Callos
executiveYeah, thanks for asking that. So we've been in touch with them. Like I said before, every one of our account managers is now on board, and so is the person heading up that group. A lot of those folks already have established connections across every one of the big payers. We've had conversations with those major payers, and honestly it's mostly an introduction to who Cytokinetics is, followed by making sure we're on the same page regarding their approach to heart failure — how they treat it, what obstacles they face, what they require. So those baseline talks have happened, and the next step, consistent with FDA rules, is essentially a pre-approval information exchange, which we'll kick off over the coming weeks. The response so far has been 12 — they appreciate that we're able to pinpoint those patients in relation to benefit in EF. That, in turn, could show where they'd aim at us when it comes to prior authorization, and we're fine with that, since it opens the door to a very particular group that stands to gain a great deal from omecamtiv. So that's hopefully a sense of how our third-quarter interactions went.
Fady Malik
executiveOne more point to mention: you're going to see considerably more published literature come out during 2022 that highlights the financial toll taken by heart failure — particularly among patients whose condition is worsening, and where a therapy built on a novel mechanism, such as omecamtiv mecarbil, might have a chance to make a difference for payers, drawing on what GALACTIC showed. And it's clear payers understand the financial toll involved in managing people with heart failure. They know about it, above all the large Medicare share among these patients, since they frequently get penalized when those patients come back into the hospital. So a therapy with a new mechanism that might bring down heart failure related events, chiefly hospitalizations, would be the sort of thing that grabs their attention, and that's something we intend to keep looking into, and it could lend support to what we have planned for omecamtiv.
Jeff Hung
analystOkay, thank you. Perhaps I heard wrong, but was it stated that COURAGE enrollment should wrap up during this year? If not, is there anything new regarding that timing, or regarding when you could more accurately determine how quickly patients are being enrolled so as to project that point? Thanks.
Fady Malik
executiveRight, what I meant to convey was that we keep enrolling throughout this year, and we also plan to continue into the next year. Our expectation is that enough patients will be enrolled to support a first interim analysis in the next year, though exactly when that happens has not yet been settled. Should that interim analysis be passed — and our hope is that it will be — the trial would go on into the next year. So no, completing enrollment within this year is not the plan.
Jeff Hung
analystOkay, thank you.
Fady Malik
executiveThank you, Jeff.
Robert Blum
executiveHey, Akash.
Akash Tewari
analystHey there, Robert. Thanks a lot for giving me the chance to ask. Could you explain what led you to choose exercise capacity as the primary endpoint instead of the comparators I might have expected, and why exercise capacity could be a more valuable endpoint for both the agency and clinicians? Also, have you received any input from either the FDA or KOLs regarding the need for long-term outcomes data after approval for our Aficamten? Thank you.
Robert Blum
executiveLet's start with Stuart on the first one, and then perhaps Fady and Stuart can take the second.
Stuart Kupfer
executiveThanks, Robert. Our work centered on assessing how function improves among obstructive HCM patients, with Aficamten compared against placebo. Given that exercise tolerance in this group is extremely limited, we zeroed in on peak VO2 — among the most stringent objective measures of exercise capacity — plus additional parameters derived from cardiopulmonary exercise testing. Rather than folding that together with something like a more subjective piece of the composite endpoint, our aim was to concentrate on what we considered the single most essential, quantitative and objective gauge of exercise capacity. As you noted, we'll also be looking at other endpoints as secondary ones, which capture symptomatic improvements — things such as the Kansas City Cardiomyopathy Questionnaire, New York Heart Association functional class, and so on. Those additional, I'd call them more traditional, endpoints are going to be assessed in SEQUOIA.
Fady Malik
executiveAnd your second question was — why do you repeat that for me Akash?
Akash Tewari
analystYes, definitely. Has any input come your way from either the FDA or KOLs regarding a requirement for outcomes data once approval is granted?
Fady Malik
executiveYes. When it comes to outcomes, my sense is that both the regulators and KOLs recognize how difficult it is to obtain outcomes data in a population that is symptomatic, even though these patients carry a very heavy burden. These individuals, in contrast to typical heart failure patients, are not admitted to the hospital, and their mortality rates tend to be fairly low, dropping well below 5% each year. So an outcomes-based trial, strictly speaking, isn't really feasible, and I believe that's clearly understood given the event rate. With that said, I think there's also an acknowledgment that the treatment created for these patients must be taken for life. Therefore, gaining solid insight into its safety over the long run matters, which is the reason we're running the open label extension with a plan for at least five years of follow-up among patients we enroll in it, that rollout of either REDWOOD or SEQUOIA, so we can better characterize how things go for these patients receiving aficamten.
Robert Blum
executiveMy view is that the arrival of novel drug treatments is going to produce stronger recognition of the results tied to an HCM diagnosis, and how those results might be altered through add-on therapy using Aficamten or Mavacamten. Also, in my opinion, you'll increasingly see papers coming from registries that address real-world evidence connected to these longitudinal studies. That puts us in a spot to gain a clearer picture of what could become achievable. And my hunch is that this will eventually influence uptake of the category, though as for your initial query about whether regulators are demanding it—I doubt that will become a factor in approval of these new medicines, at least based on what the FDA has told us.
Akash Tewari
analystThat's really useful. And if I could just ask one more thing. Could you discuss how important it is to demonstrate to the FDA that patients can be stabilized onto a safe dose from this drug class. From a regulatory standpoint, is that a focus for the agency? Thanks a lot.
Robert Blum
executiveWe definitely believe that's something achievable and possible with Aficamten, and we're hoping SEQUOIA will let us show it. If you're asking whether the FDA is actively pushing for that, given how they reviewed a different product, it wouldn't be proper for the FDA to send us any signal of that kind.
Akash Tewari
analystUnderstood. Thanks so much. Appreciate it.
Robert Blum
executiveHello Salim.
Salim Syed
analystGood afternoon, Robert and everyone, and congratulations on the progress you've made. I have a couple of questions, one about 274 and one about reldesemtiv. On 274, it seems the thesis has become much more comfortable for many long-only investors, correct? I'm wondering what you see as the gating factors — when you consider the story, what are the gating factors for 274 that are really keeping you from turning on the afterburners and beginning to develop — have path, which is a large indication, more aggressively? And I suppose we could ask the same thing about non-obstructive hypertrophic cardiomyopathy. The second question concerns reldesemtiv. Turning to how COURAGE is structured, it looks like the enrollment criteria call for patients whose ALSFRS total score is 44 or below. But when we go back to the Phase 2 results, the slow progressors — the turtle group — started at 41, and in that group there wasn't much of a gap at all between those on drug and those on placebo. So my question is what your thinking is regarding COURAGE. Is there a plan to put some kind of limit on slow progressors joining the study? Or, to put it another way, how do you make sure that by the time futility is reached, you haven't ended up with too many slow progressors enrolled? And what steps are you taking to ensure that you'll have sufficient numbers of patients with medium or fast progression, who based on the Phase 2 data would potentially demonstrate a bigger benefit? Thanks.
Robert Blum
executiveCertainly. Those are two excellent questions. We'll start with the first, about the Aficamten development program. After we saw the REDWOOD results, we've devoted considerable time across the past several months to thinking about what might come next for Aficamten beyond SEQUOIA-HCM. Here at Cytokinetics, Fady, Stuart, Steve, and others are evaluating several different trial designs, since one would expect us to broaden the development program into non-obstructive HCM as well as hefpath < >. We're not ready yet to go into detail about those, but you can count on hearing a lot more regarding our strategy in that area during 2022. Our goal is to move Aficamten forward on both of those fronts — not sequentially, but simultaneously — so that we can keep expanding our knowledge of the drug. I simply can't get into that during today's call. That said, as we work out the 2022 budgets, objectives, and the significant resources we'll need to line up to make it happen, it's absolutely top of mind in our planning. On your second question, which was about COURAGE-ALS, I'll turn things over to Fady and Stuart. I believe there may be a slight misreading of the way we've structured this trial; our focus will be on patients who are showing disease progression, though they're welcome to add more detail.
Fady Malik
executiveYeah. Salim, I'd say this is genuinely a strategy for enrichment, and the way the entry criteria have been set up is meant to bring in more of the medium and faster progressors. I can hand things to Stuart for a moment so he can explain how that functions. But in the end, it's also something we're able to track, since you can examine progression — you can examine the — work out early progression rates within the study and make sure you're putting the right patients into it in a blinded fashion. Stuart?
Stuart Kupfer
executiveYeah. So Salim, what I believe you're pointing to are the post-hoc analyses carried out using FORTITUDE-ALS along with the database. And the reason we saw signs of benefit among slow progressors, we actually saw bigger magnitudes of benefit when it comes to ALSFRS-R in patients whose disease was progressing at a medium or fast rate. What we then did was connect that rate of progression to key entry criteria, in particular a maximum ALSFRS-R of 44, and also time from symptom onset of two years. So if we take those two primary criteria and apply them, which as Fady mentioned enriches for a population of faster progressing patients, without shutting out slow progressors, but we'll end up with a bigger share of medium and faster progressing patients. With that approach, we expect this will boost the sensitivity of picking up a beneficial treatment effect with reldesemtiv.
Salim Syed
analystAll right, understood. So from your perspective, this comes down more to being able to do it according to the entry criteria, rather than needing to work it out while the trial is underway using blinded data?
Stuart Kupfer
executiveRight, that's exactly it.
Salim Syed
analystOkay. Thank you.
Robert Blum
executiveThank you, Salim.
Robert Blum
executiveAfternoon, Jason.
Jason Butler
analystHey, Robert. Appreciate you fielding these. I wanted to hear a bit more about how Aficamten might move forward in China. Beyond the PK study that's already finished, is there any additional data required before the SEQUOIA trial can be opened up in China? Also, what share of SEQUOIA enrollees do you expect might be Chinese? And could SEQUOIA on its own serve as the basis for approval in China? Or would that trial need to be supplemented by extra data or another study? Thanks.
Robert Blum
executiveGreat questions, those. We're still figuring out exactly what will be asked of us. Our working assumption, though, is that we'll be able to launch SEQUOIA in China, and on the strength of the Phase 1 results, enroll Chinese patients into that same trial, which could then help support registration both in China and beyond — the U.S., Europe, other regions. That's what we're aiming for and planning, though naturally it hinges on regulatory discussions that haven't happened yet. Our partner Ji Xing is extremely on top of all of this, and the collaboration is going very, very well. Stuart is heading up a lot of that work for Cytokinetics. Stuart, is there anything else you'd like to add?
Stuart Kupfer
executiveNo. I believe your summary captures it quite well. We definitely look to Ji Xing for direction. When it comes to China's regulatory requirements, they possess greater expertise; however, as you've — as things have been presented, we anticipate that the Phase 1 data will back the enrollment of patients in China within SEQUOIA-HCM, and that study will support registration in China.
Jason Butler
analystGreat. Thanks for taking the questions.
Robert Blum
executiveThank you.
Robert Blum
executiveHey, Charles.
Charles Duncan
analystHi there, Robert, and hello to the rest of the team. Nice work on a year that showed solid movement forward, and I appreciate you fielding my question. I've got two things I want to ask about. The first concerns omecamtiv, and the second is about reldesemtiv. On the omecamtiv NDA submission, what I'm curious about is whether you intend to put out a press release about the filing itself, or about the FDA accepting it for review, or about the submission being lodged? And then there's one point I want to get straight, and I believe this came up in what Dane asked. When you file, would the label claim be a broad one, with the data you point to being from the group of patients who saw the biggest benefit? Or would you narrow the claim you're filing to just that group?
Robert Blum
executiveRight. I'll handle those, and Fady might want to add some detail. On the communications side and the press release, our plan is to submit an NDA during this quarter, and most likely we wouldn't say anything at all until we have a read on its file ability — that is, whether FDA has filed it or has not filed it; then, for your second question, I'll turn it over to Fady to talk about the way we might handle the indication statement and where the information might sit concerning those patients who gained the most.
Fady Malik
executiveAbsolutely. I believe that when you examine various indication statements—even some that were issued not long ago—you'll find that approaches differ. That said, in most cases they mirror the overall patient group that was evaluated in the trial. Following the addition of the PARAGON data, the ENTRESTO label, as you're aware, gained another statement addressing where the benefit was most pronounced, meaning among those whose ejection fraction fell below normal. So it's possible that a qualifying statement could appear within the indication itself. What's certain is that the clinical trial section will include information on the pre-specified subgroups—one of them being ejection fraction, as you know—and it demonstrated a benefit among the lower ejection fraction group, the NYHA 3 to 4 group, and others, as well as throughout the subgroups we had pre-specified. Thus, the label has several spots where such information might appear, and in the end, predicting exactly where things land is difficult until we've had those conversations.
Charles Duncan
analystAll right. That answers my question well. It lines up with my general assumption. On METEORIC, I believe you said the trial's execution would be finished before this year ends. Could you share any indication about when the data might arrive? Might that land during the initial half of the first quarter? Also, please verify if you expect those results would subsequently go to the agency and whether they might affect the review at all. It sounds as though that could occur quite early in the review cycle, so probably not.
Robert Blum
executiveYes. I believe — providing direction on whether it's the first half or second half of the quarter for METEORIC is something we likely won't do. The trial's execution will conclude before this year is over, yet the finish will actually come quite late within the quarter; and naturally, this is a complicated study given all the central lab work involved with the CPET evaluations and similar items. Plus, the data sets take a fair amount of effort to bring together. Therefore, locking the database might not happen as quickly as would be the case in a trial driven by events.
Charles Duncan
analystAll right.
Robert Blum
executiveYet regarding the other part of what you asked, you'll need to jog my memory on it once more, since I've now lost track of it.
Charles Duncan
analystAnd what about how this affects when the review gets scheduled?
Robert Blum
executiveRight, no. Getting those results and having them this early in the quarter, I don't think that's going to — clearly, as soon as we put them out, the FDA is going to look at them, and we're hoping they'll be shown, but our expectation is that this won't affect the review. The safety data will likely be included as part of an update at some point while the review is under way, and that's all.
Charles Duncan
analystAll right. Then moving to reldesemtiv, I just have one brief question about how that study is being run; and I believe during the earlier questions, or maybe a pair back, you said something about how you're sort of enriching for patients who progress more quickly. So I suppose what I'm asking is whether you are specifically requesting a greater number of bulbar onset patients as opposed to limb onset patients, which would appear to fit with that, considering it's fewer than 2 years from when symptoms first appeared?
Robert Blum
executiveStuart, would you like to address that?
Stuart Kupfer
executiveAbsolutely, that constraint doesn't really show up when it comes to our enrollment. Patients from both of those categories are definitely being enrolled by us; however, like I said earlier, the key criteria for enriching toward patients who progress more quickly rest on the baseline LSAFRS score along with how much time has passed since symptoms began.
Charles Duncan
analystOkay. Thanks for taking the questions.
Stuart Kupfer
executiveThank you.
Robert Blum
executiveThank you, Charles.
Robert Blum
executiveGood afternoon, Rohit.
Rohit Bhasin
analystHello there, and good afternoon. Rohit here, filling in for Serge. Appreciate you taking my question. Could you discuss somewhat how the METEORIC-HF trial aligns with the gold market approach for omecamtiv? Are you anticipating a label expansion, or improved payer reimbursement?
Robert Blum
executiveCertainly. I'll have Fady address that, and perhaps Andrew may wish to chime in.
Fady Malik
executiveYeah. I believe that in the event METEORIC reads out favorably, at some point we would file a supplemental NDA seeking to broaden the label so that it incorporates METEORIC's results. The clinical benefit demonstrated there matters a great deal to patients, and it would certainly be desirable to have that reflected in the label — though that wouldn't arrive until following the initial approval of omecamtiv mecarbil. And I think the fact that — showing improved exercise capacity is something seldom observed with drugs that benefit the heart, which would make it a distinctive characteristic of omecamtiv mecarbil, assuming the trial proves positive. Perhaps I'll hand things to Andrew to see whether he'd like to add anything further on that point.
Andrew Callos
executiveAbsolutely. And when it comes to negotiating access both before and after approval, for the most part we'll rely on the data out of galactic. Should METEORIC turn out positive, that would definitely strengthen the case. We might deliver it to patients, particularly around capacity. It might bolster the argument we make about value. If patients experience improvement or might work more productively; so honestly it all hinges on how the data come out and what tweaks get made to the label. Still, my expectation wouldn't be that this meaningfully changes our broader access approach or the levels of access we achieve.
Robert Blum
executiveThe thing that it accomplishes is strengthen the rationale, since it delivers possible distinguishing advantages for patients past results, and that is a functional result. And through that, it might strengthen how omecamtiv mecarbil gets used. Still, I'm with Andrew. It probably won't push a view of things; it could quite possibly influence matters such as patient adherence and compliance, plus the way physicians eventually perceive the category.
Rohit Bhasin
analystGreat. Thank you.
Robert Blum
executiveThank you. I appreciate everyone who joined our teleconference today. We're grateful for the ongoing backing and the interest you've shown in Cytokinetics; it's a pleasure to share news about our advancement and what lies ahead. Clearly, there's a great deal happening at our company, and we intend to keep delivering on our important milestones for the rest of this year. And then, looking ahead to next year, as was noted, 2022 could prove to be a genuinely transformative year. We're eager to bring all of those updates to you. With that, operator, we're ready to wrap up the call.
Operator
operatorThank you. This does conclude today's conference call. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.